Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ligand Pharmaceuticals Incorporated stock (LGND) is currently trading at $204.81. Ligand Pharmaceuticals Incorporated PE ratio is 33.47. Ligand Pharmaceuticals Incorporated PS ratio (Price-to-Sales) is 15.23. Analyst consensus price target for LGND is $244.50. WallStSmart rates LGND as Moderate Buy.
- LGND PE ratio analysis and historical PE chart
- LGND PS ratio (Price-to-Sales) history and trend
- LGND intrinsic value — DCF, Graham Number, EPV models
- LGND stock price prediction 2025 2026 2027 2028 2029 2030
- LGND fair value vs current price
- LGND insider transactions and insider buying
- Is LGND undervalued or overvalued?
- Ligand Pharmaceuticals Incorporated financial analysis — revenue, earnings, cash flow
- LGND Piotroski F-Score and Altman Z-Score
- LGND analyst price target and Smart Rating
Ligand Pharmaceuticals Incorporated
📊 No data available
Try selecting a different time range
LGND Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Ligand Pharmaceuticals Incorporated (LGND)
LGND trades at a significant discount to its Graham intrinsic value of $286.42, offering a 35% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Ligand Pharmaceuticals Incorporated (LGND) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, eps growth. Concerns around price/sales. Overall metrics suggest strong investment potential with favorable risk/reward.
Ligand Pharmaceuticals Incorporated (LGND) Key Strengths (6)
Keeps $34 of every $100 in revenue after operating costs
Revenue surging 39.40% year-over-year
Earnings per share surging 103.20% year-over-year
Keeps $46 of every $100 in revenue as net profit
105.57% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Ligand Pharmaceuticals Incorporated (LGND) Areas to Watch (4)
Very expensive at 15.2x annual revenue
Premium pricing at 4.0x book value
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Ligand Pharmaceuticals Incorporated (LGND) Detailed Analysis Report
Overall Assessment
This company scores 71/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.5/10) while 4 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with Operating Margin at 33.60%, Profit Margin at 46.40%. Growth metrics are encouraging with Revenue Growth at 39.40%, EPS Growth at 103.20%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Return on Equity. Some valuation metrics including PEG Ratio (1.53), Price/Sales (15.23), Price/Book (4.01) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 13.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 13.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 39.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Operating Margin and Revenue Growth makes a compelling case at current levels. The key risk is Price/Sales, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ligand Pharmaceuticals Incorporated (LGND) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ligand Pharmaceuticals Incorporated is a strong growth company balancing expansion with improving profitability. Revenue reached 268M with 39% growth year-over-year. Profit margins are strong at 46.4%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 39% YoY, reaching 268M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 1350.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Ligand Pharmaceuticals Incorporated maintain 39%+ revenue growth, or will competition slow it down?
Debt management: total debt of 451M is significantly higher than cash (139M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ligand Pharmaceuticals Incorporated.
Bottom Line
Ligand Pharmaceuticals Incorporated offers an attractive blend of growth (39% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(72 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ESPINOZA, OCTAVIO Chief Financial Officer | Buy | +8 |
Data sourced from SEC Form 4 filings
Last updated: 5:13:17 AM
About Ligand Pharmaceuticals Incorporated(LGND)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.